630 related articles for article (PubMed ID: 7932398)
21. Use of the Leksell gamma knife in the treatment of prolactinoma patients.
Jezková J; Hána V; Krsek M; Weiss V; Vladyka V; Liscák R; Vymazal J; Pecen L; Marek J
Clin Endocrinol (Oxf); 2009 May; 70(5):732-41. PubMed ID: 18710463
[TBL] [Abstract][Full Text] [Related]
22. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
[TBL] [Abstract][Full Text] [Related]
23. [Results of treatment for male prolactinomas].
Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
[TBL] [Abstract][Full Text] [Related]
24. Giant invasive prolactinoma: a case report and review of nine further cases.
Davis JR; Sheppard MC; Heath DA
Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
[TBL] [Abstract][Full Text] [Related]
25. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
Delgrange E; Crabbé J; Donckier J
Horm Res; 1998; 49(5):250-3. PubMed ID: 9568811
[TBL] [Abstract][Full Text] [Related]
26. [Prolactinoma and pregnancy].
Trifonov I
Akush Ginekol (Sofiia); 2004; 43 Suppl 2():16-22. PubMed ID: 15518268
[No Abstract] [Full Text] [Related]
27. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
28. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
[TBL] [Abstract][Full Text] [Related]
29. [Macroprolactinoma resistant to bromocriptine].
López-Espinosa E; Ayala AR; Grimaldo J; Kunhardt J; Villanueva C
Arch Invest Med (Mex); 1989; 20(1):1-8. PubMed ID: 2669670
[TBL] [Abstract][Full Text] [Related]
30. Quinagolide in the management of prolactinoma.
Schultz PN; Ginsberg L; McCutcheon IE; Samaan N; Leavens M; Gagel RF
Pituitary; 2000 Dec; 3(4):239-49. PubMed ID: 11788012
[TBL] [Abstract][Full Text] [Related]
31. Long-term treatment of macroprolactinomas with CV 205-502.
Kvistborg A; Halse J; Bakke S; Bjøro T; Hansen E; Djøseland O; Brownell J; Jervell J
Acta Endocrinol (Copenh); 1993 Apr; 128(4):301-7. PubMed ID: 8098891
[TBL] [Abstract][Full Text] [Related]
32. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502.
van't Verlaat JW; Croughs RJ; Brownell J
Clin Endocrinol (Oxf); 1990 Nov; 33(5):619-24. PubMed ID: 1979262
[TBL] [Abstract][Full Text] [Related]
33. Chiasmal herniation as a complication of bromocriptine therapy.
Taxel P; Waitzman DM; Harrington JF; Fagan RH; Rothfield NF; Chen HH; Malchoff CD
J Neuroophthalmol; 1996 Dec; 16(4):252-7. PubMed ID: 8956160
[TBL] [Abstract][Full Text] [Related]
34. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
35. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
36. Normal growth and pubertal development during bromocriptine therapy in two patients with prolactinoma.
Kamel N; Uysal AR; Cesur V; Erdoğan G; Başkal N
Endocr J; 1995 Aug; 42(4):581-6. PubMed ID: 8556068
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
38. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
[TBL] [Abstract][Full Text] [Related]
39. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
40. [The best approach to treat prolactinoma].
Zárate A; Saucedo R; Basurto L
Gac Med Mex; 2004; 140(5):567-9. PubMed ID: 15559242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
